Kiniksa Pharmaceuticals Internation (KNSA) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Kiniksa Pharmaceuticals Internation in October 2026.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Kiniksa Pharmaceuticals Internation (KNSA) Stock Forecast
Analyst price target, next 12 months
$72.82
-5.1% vs today's $76.73
Price range over the last 12 months
Close to its 12-month high
Analysts covering Kiniksa Pharmaceuticals Internation have a consensus 12-month target of $72.82, below the current price of $76.73.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Kiniksa Pharmaceuticals' stock, indicating it may rise in value.
Financial Health
Kiniksa Pharmaceuticals is producing strong revenue and cash flow, showcasing healthy profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
